Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors

Cell Research

Volumn 16, Issue 3, 2006, Pages 241-259

  Xia, Dajing ^a   Moyana, Terence ^b   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adenovirus; Antitumor immunity; Cytotoxic T lymphocytes; Dendritic cells; Gene therapy; Vaccine

Indexed keywords

CANCER VACCINE; CD40 LIGAND; CYTOKINE; CYTOSINE DEAMINASE; PRODRUG; THYMIDINE KINASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL; APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CD40 LIGAND; COMBINED MODALITY THERAPY; CYTOKINES; CYTOSINE DEAMINASE; DENDRITIC CELLS; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; PRODRUGS; T-LYMPHOCYTES, CYTOTOXIC; THYMIDINE KINASE; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ANIMALIA;

EID: 33645086129     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310032     Document Type: Review

References (169)

1. Bishop JM. Cancer: the rise of the genetic paradigm. Genes Dev 1995; 9:1309-1315.
2. http://www4.od.nih.gov/oba/rac/PROTOCOL.pdf. HUMAN GENE TRANSFER PROTOCOLS. Last updated: Sep-13-04.
3. Figuredor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10:475-480.
4. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245-273.
5. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53:275-306.
6. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. Stem Cells 1999; 17:191-202.
7. Dyer MR, Herrling PL. Progress and potential for gene-based medicines. Mol Ther 2000; 1:213-224.
8. Hilleman MR, Werner JH. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med. 1954; 85:183-188.
9. rd ed. Lippincott-Raven: Philadelphia, Pa, 1996:2111-2148.
10. Gaydos CA, Gaydos JC. Adenovirus vaccine. In: Orenstein WA, Eds. Vaccines (ed 4th Edition). Philadelphia: Saunders; 2004:863-885.
11. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303:333.
12. Molinier-Frenkel V, Prevost-Blondel A, Hong SS, et al. The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 2003; 278:37175-37182.
13. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 1998; 58:1478-1485.
14. Abdel-Wahab Z, Dar M, Osanto S, et al. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther 1997; 4:33-41.
15. Kianmanesh A, Hackett NR, Lee JM, et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 2001; 12:2035-2049.
16. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995; 92:8522-8526.
17. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3:11-17.
18. Tanaka F, Abe M, Akiyoshi T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-1343.
19. Gattacceca F, Pilatte Y, Billard C, et al. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 2002; 8:3298-3304.
20. Ahmed CM, Sugarman BJ, Johnson DE, et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery. Hum Gene Ther 1999; 10:77-84.
21. Xiang J, Chen Y, Moyana T. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther 2000; 7:1023-1033.
22. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-146.
23. Akhtar N, Padilla ML, Dickerson EB, et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004; 6:106-116.
24. Lotze MT, Zitvogel L, Campbell R, et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci 1996; 795:440-454.
25. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000; 164:3112-3122.
26. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000; 96:2568-2573.
27. Feldman AL, Friedl J, Lans TE, et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99:149-153.
28. Putzer BM, Hitt M, Muller WJ, et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997; 94:10889-1094.
29. Emtage PC, Wan Y, Hitt M, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 1999; 10:697-6709.
30. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003; 3:589-596.
31. Meng RD, El-Deiry WS. Tumor suppressor genes as targets for cancer gene therapy. In: Lattime EC, Gerson SL, Eds. Gene therapy of cancer. San Diego: Academic Press, CA, 1999:3-20.
32. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
33. Zeimet AG, Riha K, Berger J, et al. New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol 2000; 60:1153-1163.
34. Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000; 164:814-819.
35. Schumacher G, Bruckheimer EM, Beham AW, et al. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 2001; 91:159-166.
36. Cirielli C, Inyaku K, Capogrossi MC, Yuan X, Williams JA. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 1999; 43:99-108.
37. Abe T, Wakimoto H, Bookstein R, et al. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther 2002; 9:228-235.
38. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58:1907-1922.
39. Brown VL, Harwood CA, Crook T, et al. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004; 122:1284-1292.
40. Kobayashi S, Shirasawa H, Sashiyama H, et al. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999; 5:4182-4185.
41. Campbell I, Magliocco A, Moyana T, Zheng C, Xiang J. Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther 2000; 7:1270-1278.
42. Kim SK, Wang KC, Cho BK, et al. Interaction between p53 and p16 expressed by adenoviral vectors in human malignant glioma cell lines. J Neurosurg 2002; 97:143-150.
43. Sandig V, Brand K, Herwig S, et al. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3:313-319.
44. Shinoura N, Muramatsu Y, Nishimura M, et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 1999; 59:5521-5528.
45. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002; 2:307-322.
46. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994; 91:3054-3057.
47. Kwon HC, Kim JH, Kim KC, et al. In vivo antitumor effect of herpes simplex virus thymidine kinase gene therapy in rat hepatocellular carcinoma: feasibility of adenovirus-mediated intra-arterial gene delivery. Mol Cells 2001; 11:170-178.
48. Maatta AM, Tenhunen A, Pasanen T, et al. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol 2004; 24:943-949.
49. Rosenfeld ME, Wang M, Siegal GP, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996; 74:455-462.
50. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2:524-530.
51. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14:227-241.
52. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65:279-289.
53. Ueno M, Koyama F, Yamada Y, et al. Tumor-specific chemoradio-gene therapy for colorectal cancer cells using adenovirus vector expressing the cytosine deaminase gene. Anticancer Res 2001; 21:2601-2608.
54. Rogulski KR, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11:67-76.
55. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11:77-89.
56. Ju DW, Tao Q, Cheng DS, et al. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 2000; 7:329-338.
57. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 2001; 166:5327-30.
58. Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sanchez-Schmitz G. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001; 13:1571-1581.
59. Lutz MB, Kukutsch N, Ogilvie AL, et al. An AdVsanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77-92.
60. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30:1813-1822.
61. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9:10-16.
62. Ishii KJ, Suzuki K, Coban C, et al. Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 2001; 167:2602-2607.
63. Rescigno M, Granucci F, Ricciardi-Castagnoli P. Molecular events of bacterial-induced maturation of dendritic cells. J Clin Immunol 2000; 20:161-166.
64. Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96:878-874.
65. Masten BJ, Olson GK, Kusewitt DF, Lipscomb MF. Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol 2004; 172:4077-4083.
66. Liu Y, Santin AD, Mane M, et al. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interferon Cytokine Res 2000; 20:21-30.
67. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183:283-287.
68. Toes RE, van der Voort EI, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998; 160:4449-4456.
69. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-6458.
70. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24:66-78.
71. Kershaw MH, Hsu C, Mondesire W, et al. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 2001; 61:7920-7924.
72. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98:8809-8814.
73. Brugger W, Schneider A, Schammann T, et al. Dendritic cell-based vaccines in patients with hematological malignancies. Ann N Y Acad Sci 2001; 938:359-362.
74. Yasukawa M, Ohminami H, Kojima K, et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Blood 2001; 98:1498-1505.
75. De Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998; 58:724-731.
76. Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002; 50:158-164.
77. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-9487.
78. Tatsumi T, Takehara T, Kanto T, et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 2001; 61:7563-7567.
79. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001; 51:1-9.
80. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001; 61:6445-6450.
81. Yoshida S, Morii K, Watanabe M, et al. The generation of antitumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors. Cancer Immunol Immunother 2001; 50:321-327.
82. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.
83. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-8519.
84. Mulders P, Tso CL, Gitlitz B, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999; 5:445-454.
85. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001; 91:749-756.
86. Santin AD, Bellone S, Ravaggi A, et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer 2002; 86:151-157.
87. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-1034.
88. Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235:540-549.
89. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98:49-56.
90. Eppler E, Horig H, Kaufman HL, Groscurth P, Filgueira L. Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA. Eur J Cancer 2002; 38:184-193.
91. Honda K, Sakaguchi S, Nakajima C, et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A 2003; 100:10872-10877.
92. Weissman D, Ni H, Scales D, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000; 165:4710-4717.
93. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with AdVsanced colorectal cancer. Hepatogastroenterology 2001; 48:347-351.
94. Schmitt WE, Stassar MJ, Schmitt W, Little M, Cochlovius B. In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells. J Cancer Res Clin Oncol 2001; 127:203-206.
95. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22:141-148.
96. Fonteneau JF, Larsson M, Bhardwaj N. Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. J Immunother 2001; 24:294-304.
97. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- specific clearance of apoptotic cells. Nature 2000; 405:85-90.
98. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-1546.
99. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000; 1:151-155.
100. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003; 198:111-122.
101. Berard F, Blanco P, Davoust J, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-1544.
102. Jenne L, Arrighi JF, Jonuleit H, Saurat JH, Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000; 60:4446-4452.
103. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991-1045.
104. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191:423-433.
105. Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191:411-416.
106. Rovere P, Vallinoto C, Bondanza A, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161:4467-4471.
107. Rovere P, Sabbadini MG, Vallinoto C, et al. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol 1999; 66:345-349.
108. Pietra G, Mortarini R, Parmiani G, et al. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res 2001; 61:8218-8226.
109. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001; 61:8105-8109.
110. Feng H, Zeng Y, Whitesell L, et al. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 2001; 97:3505-3512.
111. Zheng H, Dai J, Stoilova D, et al. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol 2001; 167:6731-6735.
112. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93:539-548.
113. Rughetti A, Biffoni M, Sabbatucci M, et al. Transfectedhuman dendritic cells to induce antitumor immunity. Gene Ther 2000; 7:1458-1466.
114. Irvine AS, Trinder PK, Laughton DL, et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-1278.
115. Wei Y, Li J, Chen WY, et al. Enhanced transgene expression and effective in vivo antitumor immune responses initiated by dendritic progenitors transfected with a nonviral T7 vector expressing a model tumor antigen. J Immunother 2000; 23:75-82.
116. Di Nicola M, Carlo-Stella C, Milanesi M, et al. Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. Br J Haematol 2000; 111:344-350.
117. Lapointe R, Royal RE, Reeves ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol 2001; 167:4758-4764.
118. Willis RA, Bowers WJ, Turner MJ, et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 2001; 12:1867-1879.
119. Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001; 75:9493-9501.
120. Motta I, Andre F, Lim A, et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 2001; 167:1795-1802.
121. Maruyama K, Akiyama Y, Nara-Ashizawa N, et al. Adenovirus-Mediated MUC1 gene transduction into human blood-derived dendritic cells. J Immunother 2001; 24:345-353.
122. Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. J Mol Med 2003; 81:585-596.
123. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-1708.
124. Ribas A, Butterfield LH, Hu B, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66.
125. Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Gene Ther 2001; 8:1255-1263.
126. Nikitina EY, Clark JI, Van Beynen J, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7:127-135.
127. Okada N, Masunaga Y, Okada Y, et al. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther 2003; 10:1891-1902.
128. + T cells in patients with melanoma. J Immunol 2000; 164:3402-3412.
129. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998; 161:5607-5613.
130. Chen Y, Emtage P, Zhu Q, et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001; 8:316-323.
131. zum Buschenfelde CM, Metzger J, Hermann C, et al. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 2001; 167:1712-1719.
132. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11:797-806.
133. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163:174-183.
134. Zhang W, Chen Z, Li F, et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108:177-188.
135. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63:6378-6386.
136. Matsuyoshi H, Senju S, Hirata S, et al. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004; 172:776-786.
137. Xia DJ, Zhang WP, Zheng S, et al. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther 2002; 9:592-601.
138. Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther 2002; 9:202-208.
139. Ozawa H, Ding W, Torii H, et al. Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity. J Invest Dermatol 1999; 113:999-1005.
140. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996; 17:214-217.
141. Akiyama Y, Watanabe M, Maruyama K, et al. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 2000; 7:2113-2121.
142. Furumoto K, Arii S, Yamasaki S, et al. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer 2000; 87:665-672.
143. Vitiello PF, Rausch MP, Horowitz KM, Kurt RA. Secondary lymphoid-tissue chemokine induced modulation of T cells. Immunol Invest 2004; 33:235-249.
144. Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002; 168:338-347.
145. Hsieh CL, Pang VF, Chen DS, Hwang LH. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum Gene Ther. 1997; 8:1843-1854.
146. Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J Gene Med. 2004; 6:857-868.
147. Liu Y, Xia D, Li F, Zheng C, Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005; 12:122-132..
148. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45:491-503.
149. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995; 55:4824-4829.
150. Mizuguchi H, Nakagawa T, Toyosawa S, et al. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res 1998; 58:5725-5730.
151. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000; 165:6278-6286.
152. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044.
153. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6:1328-1334.
154. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:6528-6534.
155. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
156. Xiang J, Qi Y, Chen Y. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF. Cancer Gene Ther 1997; 4:353-358.
157. Lu Y, Yamauchi N, Koshita Y, et al. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther 2001; 8:499-507.
158. Marr RA, Addison CL, Snider D, et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 1997; 4:1181-1188.
159. Marr RA, Hitt M, Gauldie J, Muller WJ, Graham FL. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene her 1999; 6:465-474.
160. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14:49-57.
161. Grewal IS and Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135.
162. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-483.
163. Bancherau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
164. Hart DN. Dendritic cells: unique leukocytes populations which control the primary immune response. Blood 1997; 90:3245-3287.
165. Shreedhar V, Moodycliffe AM,Ullrich SE, et al. Dendritic cells require T cells for functional maturation in vivo. Immunity 1999; 11:625-636.
166. Moodycliffe AM, Shreedhar V, Ullrich SE, et al. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med 2000; 191:2011-2020.
167. + cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000; 192:145-150.
168. + T cells in vitro, whereas CD40 ligation is essential. J Immunol 2001; 167:6247-6255.
169. Watanabe S, Kagamu H, Yoshizawa H, et al. The Duration of Signaling through CD40 Directs Biological Ability of Dendritic Cells to Induce Antitumor Immunity. J Immunol 2003; 171:5828-5836.